Tags

Type your tag names separated by a space and hit enter

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Vaccine. 2007 May 04; 25(18):3669-78.V

Abstract

We have developed a web-based user-interface (web interface) to enhance the usefulness of health-economic evaluations to support decision making (http://pcv.healtheconomics.nl). It allows the user to interact with a health-economic model to evaluate predefined and customized scenarios and perform sensitivity analysis. To explore its usefulness, it was applied to an evaluation of cost-effectiveness of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7), that was used to support a policy decision on the inclusion of PCV7 in the national vaccination program (NVP) of the Netherlands. We used a decision-tree analytic model to project the impact of infant vaccination with four doses of PCV7 on an annual cohort of infants born in the Netherlands. The base-case analysis includes the beneficial effects on unvaccinated individuals (herd protection). Additional scenarios varying the number of doses, discount rate for effects and the number of serotypes in the vaccine were evaluated and can be analysed on the web. Our model projects a base-case incremental cost-effectiveness ratio (iCER) of euro14,000 (95% uncertainty interval (UI): 9,800-20,200) per quality adjusted life year (QALY) or euro15,600 (95% UI: 11,100-23,900) per life year gained (LYG).

Authors+Show Affiliations

Social Pharmacy, Pharmacoepidemiology & Pharmacotherapy, University of Groningen, and Base-Case, Healthcare Decision Support, Groningen, The Netherlands. g.hubben@rug.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17360082

Citation

Hubben, G A A., et al. "Enhanced Decision Support for Policy Makers Using a Web Interface to Health-economic Models--illustrated With a Cost-effectiveness Analysis of Nation-wide Infant Vaccination With the 7-valent Pneumococcal Conjugate Vaccine in the Netherlands." Vaccine, vol. 25, no. 18, 2007, pp. 3669-78.
Hubben GA, Bos JM, Glynn DM, et al. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2007;25(18):3669-78.
Hubben, G. A., Bos, J. M., Glynn, D. M., van der Ende, A., van Alphen, L., & Postma, M. J. (2007). Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine, 25(18), 3669-78.
Hubben GA, et al. Enhanced Decision Support for Policy Makers Using a Web Interface to Health-economic Models--illustrated With a Cost-effectiveness Analysis of Nation-wide Infant Vaccination With the 7-valent Pneumococcal Conjugate Vaccine in the Netherlands. Vaccine. 2007 May 4;25(18):3669-78. PubMed PMID: 17360082.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. AU - Hubben,G A A, AU - Bos,J M, AU - Glynn,D M, AU - van der Ende,A, AU - van Alphen,L, AU - Postma,M J, Y1 - 2007/02/05/ PY - 2005/12/09/received PY - 2006/12/05/revised PY - 2007/01/11/accepted PY - 2007/3/16/pubmed PY - 2007/6/30/medline PY - 2007/3/16/entrez SP - 3669 EP - 78 JF - Vaccine JO - Vaccine VL - 25 IS - 18 N2 - We have developed a web-based user-interface (web interface) to enhance the usefulness of health-economic evaluations to support decision making (http://pcv.healtheconomics.nl). It allows the user to interact with a health-economic model to evaluate predefined and customized scenarios and perform sensitivity analysis. To explore its usefulness, it was applied to an evaluation of cost-effectiveness of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7), that was used to support a policy decision on the inclusion of PCV7 in the national vaccination program (NVP) of the Netherlands. We used a decision-tree analytic model to project the impact of infant vaccination with four doses of PCV7 on an annual cohort of infants born in the Netherlands. The base-case analysis includes the beneficial effects on unvaccinated individuals (herd protection). Additional scenarios varying the number of doses, discount rate for effects and the number of serotypes in the vaccine were evaluated and can be analysed on the web. Our model projects a base-case incremental cost-effectiveness ratio (iCER) of euro14,000 (95% uncertainty interval (UI): 9,800-20,200) per quality adjusted life year (QALY) or euro15,600 (95% UI: 11,100-23,900) per life year gained (LYG). SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17360082/Enhanced_decision_support_for_policy_makers_using_a_web_interface_to_health_economic_models__illustrated_with_a_cost_effectiveness_analysis_of_nation_wide_infant_vaccination_with_the_7_valent_pneumococcal_conjugate_vaccine_in_the_Netherlands_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(07)00086-2 DB - PRIME DP - Unbound Medicine ER -